Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma



Status:Archived
Conditions:Cancer, Gastrointestinal
Therapuetic Areas:Gastroenterology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:May 2009
End Date:March 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma


The ongoing study is a Phase II, open-label study to evaluate the efficacy of MBP-426 at a
dose of 170 mg/m2 in combination therapy in patients with second line metastatic gastric,
gastro-esophageal junction or esophageal adenocarcinoma.



We found this trial at
3
sites
Huntsman Cancer Hospital
Salt Lake City, Utah 84112
1511
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Mary Crowley Medical Research Center
Dallas, Texas 75201
911
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials